Vinorelbine
Angiosarcoma
QuantumLeap Healthcare CollaborativePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
55 Active assets in the Angiosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Pembrolizumab Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Encequidar QuantumLeap Healthcare Collaborative | Phase 2 | CCC |
Trilaciclib QuantumLeap Healthcare Collaborative | Phase 2 | CCC |
Rilvegostomig QuantumLeap Healthcare Collaborative | Phase 2 | CCC |
View all 50 →
Same molecule, other indications
Vinorelbine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →